MedicQuant ApS
Nøgletal
- Afkastningsgrad
- -9,6 %
- Egenkapitalforrentning
- -7,4 %
- Likviditetsgrad
- 593,6 %
- Soliditetsgrad
- 87,3 %
Resultat
| Regnskabsperiode | |
|---|---|
Bruttoresultat | 1.911.164 |
Driftsresultat | -1.098.767 |
Finansielle indtægter | 32.888 |
Finansielle omkostninger | 10.732 |
Skat af årets resultat | -334.649 |
Årets resultat | -741.962 |
Medarbejdere
| Regnskabsperiode | |
|---|---|
Gns. ansatte | 7 |
Personaleomkostninger | 2.994.376 kr. |
Balance
| Regnskabsperiode | |
|---|---|
Likvider | 936.529 |
Kortfristede aktiver | 2.260.546 |
Langfristede aktiver | 9.197.312 |
Aktiver i alt | 11.457.858 |
Egenkapital | 10.000.226 |
Forpligtelser i alt | 1.457.632 |
Kortfristede forpligtelser | 380.797 |
Arbejdskapital
| Regnskabsperiode | |
|---|---|
Tilgodehavender fra salg og tjenesteydelser | 0 |
Andre kortfristede tilgodehavender | 153.465 |
Leverandørgæld | 71.533 |
Kapital og udbytte
| Regnskabsperiode | |
|---|---|
Selskabskapital | 90.839 |
Overført resultat | -9.342.142 |
Investeringer og aktiver
| Regnskabsperiode | |
|---|---|
Langfristede investeringer og tilgodehavender | 120.486 |
Materielle anlægsaktiver | 133.765 |
Højdepunkter fra årsrapporten
Forretning og udvikling
Description of key activities of the companyThe purpose of the company is to develop and manufacture medical devices and reagents for in vitro diagnostic purpose.
Significant changes in the company's activities and financial mattersThe gross profit for the year totals DKK 1.911 thousand against DKK 1.094 thousand last year. Profit or loss from ordinary activities after tax totals DKK -742 thousand against DKK -501 thousand last year.
Financial resourcesAs of the balance sheet date, the company does not have sufficient funds to continue the development of its project. During February 2026, Management has however secured in excess of DKK 22 million to support the continued development of the project towards commercialisation. Based on this, management has prepared the financial statements as a going concern.
Risici og væsentlige forhold
1.
Financial resourcesAs of the balance sheet date, the company does not have sufficient funds to continue the development of its project. During February 2026, Management has however secured in excess of DKK 22 million to support the continued development of the project towards commercialisation. Based on this, management has prepared the financial statements as a going concern.
Events occurring after the end of the financial yearApart from the above, no events have occurred after the balance sheet date of material importance to the annual report for 2025.
Forpligtelser og sikkerhedsstillelser
10.Contractual obligations and contingencies, etc.
DKK in thousands…
Se op til 9 års regnskabshistorik ved at oprette en gratis bruger
Opret gratis bruger